9:42 ET -- Roche is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The Swiss pharmaceutical company announced a deal to buy Carmot Therapeutics for $2.7 billion with up to $400 million in additional payments based on drug-development milestones. Roche said it would be gaining Carmot's research-and-development portfolio, including drugs it's developing to treat obesity and type-1 and type-2 diabetes. Dow Jones & Co. owns Factiva. (susan.solan@wsj.com)

(END) Dow Jones Newswires

December 04, 2023 09:57 ET (14:57 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Gráfica de Acción Histórica
De Feb 2025 a Mar 2025 Haga Click aquí para más Gráficas Roche (QX).
Roche (QX) (USOTC:RHHBY)
Gráfica de Acción Histórica
De Mar 2024 a Mar 2025 Haga Click aquí para más Gráficas Roche (QX).